To own Science Applications International, you need to be comfortable with a slow top line and a story focused on mix, efficiency and contract quality rather than rapid expansion. The near term swing factor is still how well Project ORBIT, AI and automation work through costs while government budget scrutiny and contract roll offs, such as the RITS loss, weigh on organic growth.
The CFO transition to Kenneth Crews looks more like continuity than a reset for those catalysts. His background in defense and government services finance fits the existing focus on margins, capital discipline and higher value mission work, so the immediate risk reward balance around execution, pricing pressure and portfolio shift does not materially change.
The most relevant piece of news is Crews joining as Chief Financial Officer Elect on October 30, 2026, then stepping into the full CFO and Executive Vice President role in December. The board is effectively pairing a finance leader used to enterprise wide functions, including M&A, treasury and investor relations, with a business that is already leaning on cost programs and capital allocation to support earnings.
At the same time, Prabu Natarajan’s move to permanently run the Civilian Business Group while still overseeing Enterprise Operations and Project ORBIT keeps operational know how tied directly to a segment that depends on federal civilian contracts. For catalysts around ORBIT savings, AI driven efficiency and the shift away from commoditized IT, investors now watch how tightly Natarajan executes delivery while Crews manages balance sheet risk, including debt, and margin targets.
For Science Applications International, the analyst story is built around relatively steady revenue, modest margin lift and incremental earnings progress rather than rapid expansion. Consensus assumes the top line stays broadly flat over the next 3 years, with profit margins moving from 5.1% today to 5.6% by 2029 as Project ORBIT savings, automation and mix shift away from commoditized IT feed through to profitability.
Analysts see earnings today at about US$380.0 million and expect them to reach roughly US$424.8 million by 2029, which implies an earnings increase of about US$44.8 million on their base case, with more optimistic views stretching earnings as high as US$505.4 million. That profile relies on a business that keeps wringing more profit from a similar revenue base rather than expanding aggressively into new volume, supported by share count declining an expected 7.0% per year over the next 3 years as buybacks continue to shrink the equity base.
Valuation assumptions sit on top of those earnings targets. To line up with the consensus view, investors would effectively be underwriting 2029 revenue of about US$7.6b and earnings of roughly US$424.8 million, with Science Applications International trading on a P/E of 13.4 times those future profits compared with 14.5 times today and an industry multiple of 22.2 times, all discounted back using an 8.3% rate. With the current share price around US$131.57 and the average price target at US$132.56, the implied upside of about 0.7% suggests analysts, on balance, see the stock as close to fairly priced against these flat revenue, higher margin expectations.
Science Applications International's narrative projects about US$7.6b in revenue and roughly US$424.8 million in earnings by 2029. This setup rests on broadly flat yearly revenue trends and an earnings increase of about US$44.8 million from current earnings of roughly US$380.0 million.
Uncover why Science Applications International's fair value indicates an 8% potential downside to its current price that leaves little room for error.
One bullish twist you may want to explore is how Project ORBIT could play out very differently under Science Applications International’s new CFO. Before this news, the most optimistic analysts were sketching out about US$7.9b of 2029 revenue and roughly US$504.5 million of earnings. Those forecasts reflect a much richer margin story than the flat consensus path. The leadership reshuffle has not been baked into either camp yet, so this is a good moment to compare those competing views and decide which feels closer to your own expectations.
Explore 4 other Science Applications International fair value estimates, including one that suggests up to 75% upside from the current price!
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
If you want to stress test your view on Science Applications International, it helps to compare it with other businesses that share some of the same financial traits. The Simply Wall St Screener is built for exactly that kind of side by side work, so you can benchmark quality, balance sheet strength and payout profiles in minutes.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com